Shattuck Labs (STTK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for May 28, 2026, to be held virtually at 11:30 AM Eastern Time.
Stockholders of record as of April 2, 2026, are eligible to participate and vote.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report, are available online or by request.
Voting matters and shareholder proposals
Election of three Class III director nominees to serve until the 2029 Annual Meeting: Taylor Schreiber, Helen M. Boudreau, and Clay Siegall.
Ratification of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.
Advisory vote on the compensation of named executive officers (say-on-pay).
Advisory vote on the frequency of future say-on-pay votes.
Approval of an amendment and restatement of the 2020 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends voting "FOR" each director nominee and all proposals except Proposal 4, where "1 YEAR" is recommended for the frequency of say-on-pay votes.
Latest events from Shattuck Labs
- SL-325, a first-in-class DR3 antagonist for IBD, shows superior preclinical efficacy and durability.STTK
Corporate presentation - SL-325, a first-in-class DR3 antagonist for IBD, shows superior preclinical efficacy and safety.STTK
Corporate presentation - SL-325 offers a first-in-class DR3 blockade with durable efficacy and low immunogenicity for IBD.STTK
Corporate presentation - SL-325 completed Phase 1 with strong safety; $208.3M cash funds operations into 2029.STTK
Q2 2026 - Lead DR3 antibody SL-325 shows promise for IBD with strong safety and low immunogenicity.STTK
Corporate presentation - SL-325 showed durable DR3 blockade, low immunogenicity, and is advancing to phase IIb in Crohn's.STTK
Study result - SL-325, a first-in-class DR3 antibody for IBD, advances with strong preclinical data and funding.STTK
Corporate presentation - SL-325 Phase 1 enrollment completed; net loss rose to $14.8M, cash runway into 2029.STTK
Q1 2026 - DR3 blocking antibodies for IBD aim to surpass TL1A blockers in efficacy and safety, with key trials imminent.STTK
TD Cowen 46th Annual Health Care Conference